Segall Bryant & Hamill LLC Has $12.91 Million Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Segall Bryant & Hamill LLC grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 66.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 42,369 shares of the company's stock after purchasing an additional 16,872 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.15% of Medpace worth $12,909,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Jones Financial Companies Lllp raised its position in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares in the last quarter. Proficio Capital Partners LLC increased its stake in shares of Medpace by 4.1% during the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after acquiring an additional 29 shares during the period. Independent Advisor Alliance raised its holdings in Medpace by 7.4% during the fourth quarter. Independent Advisor Alliance now owns 1,011 shares of the company's stock worth $336,000 after purchasing an additional 70 shares in the last quarter. HighTower Advisors LLC lifted its position in Medpace by 4.7% in the fourth quarter. HighTower Advisors LLC now owns 3,140 shares of the company's stock worth $1,043,000 after purchasing an additional 142 shares during the period. Finally, Sequoia Financial Advisors LLC boosted its stake in Medpace by 10.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 882 shares of the company's stock valued at $293,000 after purchasing an additional 84 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Trading Down 2.3%

MEDP stock traded down $7.29 during mid-day trading on Friday, reaching $311.87. 375,011 shares of the stock traded hands, compared to its average volume of 379,236. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $441.27. The stock's fifty day moving average is $307.15 and its 200-day moving average is $318.21. The company has a market cap of $8.96 billion, a P/E ratio of 23.81, a P/E/G ratio of 5.69 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $3.06 by $0.61. Medpace had a net margin of 19.31% and a return on equity of 54.36%. The business had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. During the same quarter in the prior year, the firm earned $3.20 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on MEDP shares. TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and cut their price objective for the company from $370.00 to $328.00 in a report on Monday, April 14th. Leerink Partners started coverage on shares of Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. Robert W. Baird reduced their price objective on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. William Blair reaffirmed a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Finally, Leerink Partnrs raised shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Twelve investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Medpace presently has a consensus rating of "Hold" and an average target price of $344.82.

Insider Buying and Selling at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director directly owned 2,998 shares of the company's stock, valued at approximately $904,856.36. This represents a 36.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.